Browsing Tag
Tryngolza
2 posts
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
Biotech rivals clash as Arrowhead sues Ionis over RNA-based triglyceride therapy
Arrowhead sues Ionis over APOC3 patent dispute as plozasiran nears FDA approval. Discover what’s at stake in this RNA-based biotech rivalry.